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Abstract The six types of pattern recognition molecules
(PRMs) that initiate complement via the lectin pathway (LP)
comprise collectins and ficolins. The importance of having
various PRMs to initiate the LP is currently unclear.
Mannan-binding lectin (MBL) is a collectin member of the
LP PRMs. MBL deficiency is common with mild clinical
consequence. Thus, the lack of MBL may be compensated
for by the other PRMs. We hypothesized that variants
FCN2+6424 and FCN3+1637delC that cause gene-dose-
dependent reduction in ficolin-2 and ficolin-3 levels, respec-
tively, may be rare in MBL-deficient individuals due to the
importance of compensation within the LP. The aim of this
study was to investigate the distribution and frequency of
these variants among MBL2 genotypes in healthy subjects.
The allele frequency of FCN2+6424 and FCN3+1637delC
was 0.099 and 0.015, respectively, in the cohort (n=498). The
frequency of FCN2+6424 tended to be lower among MBL-
deficient subjects (n=53) than among MBL-sufficient sub-
jects (n=445) (0.047 versus 0.106, P=0.057). In addition,
individuals who were homozygous for FCN2+ 6424 were
sufficient MBL producers. The frequency of FCN3 +
1637delC did not differ between the groups. The frequency
of FCN2+ 6424 was similar in FCN3+ 1637delC carriers
(n=15) versus wild type (n=498). Furthermore, subjects that
were heterozygote carriers of both FCN2+6424 and FCN3+
1637delC were sufficient MBL producers. In conclusion,
FCN2+6424 carriers with MBL deficiency tend to be rare
among healthy individuals. MBL-deficient individuals with
additional LP PRM defects may be at risk to morbidity.
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Introduction
The lectin pathway (LP) is the most recently discovered of the
three complement activation pathways. It is initiated by one of
the six pattern recognition molecules (PRMs), either mannan-
binding lectin (MBL), collectin kidney-1 (CL-K1), collectin
liver-1 (CL-L1), ficolin-1 (M-ficolin), ficolin-2 (L-ficolin) or
ficolin-3 (H-ficolin) (Henriksen et al. 2013; Kjaer et al. 2013).
The PRMs bind specific molecular patterns on pathogens,
apoptotic cells and cellular debris as they circulate in serum
complexed with three serine proteases (MASP-1–3) and two
non-enzymatic proteins with regulatory functions: MAP1 and
sMAP (Dahl et al. 2001; Degn et al. 2009; Sato et al. 1994;
Skjoedt et al. 2011; Stover et al. 1999; Takahashi et al.
1999; Thiel et al. 1997). Upon binding, MASP-1 activates
MASP-2 which subsequently cleaves complement factors
C2 and C4 resulting in the activation of the complement
cascade with the generation of inflammatory mediators
(C3a and C5a), assembly of the membrane attack complex
(MAC) and opsonisation (Degn et al. 2012; Héja et al.
2012; Takahashi et al. 2008).
The collectins (MBL, CL-K1 and CL-L1) and ficolins are
similar in structure (Kjaer et al. 2013). They are oligomers and
share amino terminal collagen-like stalk that interacts with the
MASPs. They differ at the carboxyl terminal where the
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ficolins contain fibrinogen-like recognition domain and the
collectins contain C-type carbohydrate recognition domain.
Despite having a common structure, ficolin-2 and ficolin-3
are only 48 % identical by sequence (Sugimoto et al. 1998).
Both ficolin-2 and ficolin-3 have been shown to bind dying
host cells and mediate their clearance through complement
activation via the LP (Honoré et al. 2007; Jensen et al. 2007;
Kuraya et al. 2005). Ficolin-2 binds various clinically relevant
pathogens including those affecting the respiratory system,
whereas ficolin-3 does not (Hummelshøj et al. 2012; Krarup
et al. 2005; Pan et al. 2012). However, recently, it was shown
t h a t f i c o l i n - 3 b i n d s e n t e r o p a t h o g e n i c a n d
enteropathoaggregative Escherichia coli (Sahagún-Ruiz
et al. 2015). Furthermore, the first evidence of antimicrobial
activity of ficolin-3 was recently reported against the enteric
commensal and opportunistic gut bacteria Hafnia alvei
(Michalski et al. 2015a). Thus, there appears to be a link
between ficolin-3 and the gut. Notably, ficolin-3 is resistant
to collagenases (whereas the other ficolins and collagens are
not) and this may reflect the site of its antimicrobial activity,
i.e. in the gastrointestinal tract (Hummelshoj et al. 2008).
The concentration of MBL in serum ranges from <10–12,
200 ng/ml in adults, with a median of 1340 ng/ml (Sallenbach
et al. 2011). This large range span can be explained by com-
binations of functional single nuclear polymorphisms (SNPs)
in exon 1 and in the promoter of theMBL2 gene (Garred et al.
2003). The SNPs in exon 1 have been named variant allele D
(the codon 52 allele or p.Arg52Cys), B (the codon 54 allele or
p.Gly54Asp) and C (the codon 57 allele or p.Gly57Glu).
Collectively, they are referred to as the O allele, whereas the
normal wild-type allele is referred to as the A allele. The O
allele gives rise to dysfunctional forms ofMBL that are unable
to bind to their ligands (Lipscombe et al. 1995; Madsen et al.
1994; Sumiya et al. 1991). The SNPs in the MBL2 promoter
region are located at position −50 (H/L) and −221 (X/Y) and
at position +4 (P/W) in the 5′-untranslated portion of exon 1
(Madsen et al. 1995; Madsen et al. 1998; Steffensen et al.
2000). The variant at position −221 (X allele) has the strongest
downregulating effect on MBL expression. A combination of
the SNPs in exon 1 and MBL2 promoter determines various
MBL2 genotypes. The XA/O and O/O genotypes are generally
referred to as MBL-deficient genotypes as they give rise to
undectable MBL levels (<10 ng/ml) (Eisen et al. 2008).
Ficolin-2 is expressed in the liver and serum concentration
varies from 1340 to 14,700 ng/ml in adults, with a median of
3370 ng/ml (Sallenbach et al. 2011). The +6424 G>T variant
in exon 8 of the FCN2 gene leads to amino acid substitution
within the firbrinogen-like domain of ficolin-2, and the muta-
tion has a gene-dose effect on ficolin-2 serum levels (Munthe-
Fog et al. 2007). The median serum levels of wild-type (G/G),
heterozygotes (G/T) and homozygotes (T/T) have been shown
to be 5100, 2200 and 900 ng/ml, respectively (Kilpatrick et al.
2013; Munthe-Fog et al. 2007). Thus, homozygosity does not
lead to absolute ficolin-2 deficiency but is generally referred
to as ficolin-2 insufficiency (Kilpatrick and Chalmers 2012).
Concomitant with the variant’s downregulating effect is in-
creased binding affinity for GlcNAc (Hummelshoj et al.
2005). Allele frequency has been reported to be between
0.12 and 0.14 in Caucasians (Damman et al. 2012; Herpers
et al. 2006; Kilpatrick et al. 2013; Munthe-Fog et al. 2007;
Ojurongbe et al. 2012). Low levels of ficolin-2 have been
associated with prematurity, low birth weight and infections
in neonates, childhood infections combined with allergic dis-
eases and preeclampsia (Atkinson et al. 2004; Cedzynski et al.
2009; Swierzko et al. 2009; Wang et al. 2007). In addition, the
FCN2+6424 variant has been linked to the early onset of
Pseudomonas aeruginosa in cystic fibrosis patients
(Haerynck et al. 2012).
Ficolin-3 is the most abundant LP PRM in serum and the
most potent LP activator in vitro (Hummelshoj et al. 2008). Its
concentration varies tenfold (6100–60,300 ng/ml) in adults,
with a median of 19,500 ng/ml (Sallenbach et al. 2011). The
+1637delC variant in exon 5 of the FCN3 gene is a frameshift
mutation leading to the truncation of the C-terminal end of the
ficolin-3 protein (Munthe-Fog et al. 2008). The variant has
gene-dose-dependent effect on ficolin-3 serum levels, and ho-
mozygotes have no detectable ficolin-3 in serum (Michalski
et al. 2011; Munthe-Fog et al. 2009; Munthe-Fog et al. 2008).
Gene frequency has been reported to be rare (0.01–0.02) sug-
gesting the crucial functions of ficolin-3 (Michalski et al.
2011; Munthe-Fog et al. 2009). Congenital ficolin-3 deficien-
cy (+1637delC homozygotes) has so far only been confirmed
in six individuals including two prematures, one infant and
three adults. These subjects were affected by various morbid-
ities (though nothing in common), such as invasive necrotiz-
ing eneterocolitis (NEC), perinatal Streptococcus agalactiae
infections, congenital heart disease, recurrent severe pulmo-
nary infections, brain abscesses, and severe nephrotic syn-
drome (Michalski et al. 2011; Michalski et al. 2015b;
Munthe-Fog et al. 2009; Schlapbach et al. 2011). One of the
homozygous adult was found in a healthy control group
(Metzger et al. 2015).
MASP-2 serum levels ranges from 125 to 1150 ng/ml, with
a median of 416 ng/ml (Sallenbach et al. 2011). The p.D120G
mutation results in impaired binding to bothMBL and ficolins
(Stengaard-Pedersen et al. 2003; Thiel et al. 2009) and influ-
ences MASP-2 serum levels in a gene-dose-dependent man-
ner. Homozygotes for the p.D120G variant have no detectable
MASP-2 in serum and no MBL-mediated activation of com-
plement (Stengaard-Pedersen et al. 2003). Allele frequency is
0.039 in Danish Caucasians (Thiel et al. 2007). Interestingly,
the allele is not found in other populations such as Hong Kong
Chinese, Zambian Africans and Amerindians in Brazil (Thiel
et al. 2007). A total of thirteen p.D120G homozygotes have
been published from case-control studies since the first case
that was reported in the year 2003 (Stengaard-Pedersen et al.
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2003). Six were unaffected or healthy (Garcia-Laorden et al.
2006; Olszowski et al. 2014; Segat et al. 2008; Sokolowska
et al. 2015; Stover et al. 2005). Seven were detected in cohorts
of recurrent respiratory infections, cystic fibrosis, colorectal
cancer, hepatocellular carcinoma and pulmonary tuberculosis
(Cedzynski et al. 2009; Cedzynski et al. 2004; Olesen et al.
2006; Segat et al. 2008; Sokolowska et al. 2015). Thus, the
impact of MASP-2 deficiency (p.D120G homozygosity) in
disease association is uncertain and it appears that homozy-
gotes are found by chance. One might conclude from this that
the LP is dispensible or redundant for human health because
the current knowledge is that MASP-2 is crucial for LP com-
plement activation. There are probably unidentified molecules
and functions involved in the LP that could explain why
MASP-2 deficiency is relatively common in apparently
healthy individuals. In certain situations, being a p.D120G
carrier may be relevant such as in the medical intensive care
unit where it has been reported that the p.D120G allele was
associated with increased risk of early death (Henckaerts et al.
2009).
Numerous studies have linked MBL deficiency with in-
creased susceptibility to a variety of infectious and autoim-
mune diseases (reviewed in (Bjarnadottir and Ludviksson
2010; Dommett et al. 2006; Eisen and Minchinton 2003;
Kilpatrick 2002; Thiel et al. 2006; Worthley et al. 2005).
Several recent case-control studies have been investigating
alternations in the distribution patterns of serum concentration
of the early LP components in disease pathogenesis such as in
patient groups with systemic lupus erythematosis (SLE), he-
modialysis, pulmonary tuberculosis and acute liver failure
(Chalmers et al. 2015; Ishii et al. 2011; Laursen et al. 2015;
Troldborg et al. 2015a; Troldborg et al. 2015b). However,
there are various factors that can influence serum levels, such
as acute phase response and medication. Thus, genetic analy-
sis may in certain settings provide more lines of reliable infor-
mation. Studies involving determination on the combination
of LP variants within LP genotypes remain scarce. To our
knowledge, this is the first study that describes the frequency
and distribution of the downregulating variants in the FCN2,
FCN3 andMASP2 genes amongMBL2 genotypes in a healthy
Caucasian population.
Material and methods
Subjects and samples
Between April and May 2010, EDTA blood was collected
from a total of 498 volunteer blood donors from the
Icelandic Blood Bank, and genomic DNAwas isolated using
high-salt procedure (Miller et al. 1988). The donors were
Caucasians with age range of 18–60 years, and 125 were
women and 375 were men. Informed consent was obtained
from participants and only ethnic origin, gender and age was
recorded. The study was approved by the Bioethics
Committee of Iceland and the Data Protection Committee of
Iceland.
Genotyping
A real-time polymerase chain reaction (PCR) with subsequent
melting curve (Tm) analysis on amplicons was used to detect
functional variants (rs1800450, rs1800451, rs5030737) in ex-
on 1 and promoter (rs7096206) of the MBL2 gene with the
LightCycler Instrument (Roche Diagnostics) using a previ-
ously described method (Steffensen et al. 2003). FCN2
genotyping was carried out using a sequence-specific primer
PCR (SSP-PCR) to detect the functional variant (rs7851696)
in exon 8 (Szala et al. 2013). Restriction fragment length
polymorphism PCR (RFLP-PCR) was used to detect the base
deletion 1637delC (rs28357092) in the FCN3 gene (Michalski
et al. 2011). MASP2 genotyping was carried out using SSP-
PCR to detect the mutation (rs72550870) in the MASP2 gene
(Boldt et al. 2011).
Statistical analysis
Allele frequency was compared between two and three geno-
type subgroups within the blood donor cohort using the chi-
square test. When comparing more than three genotype sub-
groups, the Kruskal-Wallis H test was used followed by the
Dunn’s multiple comparison post hoc test. The level of signif-
icance was set at 0.05 and the program package SPSS 11.0
(SPSS, Inc, Chicago, Ill) was used for processing the data.
Results
Frequency ofMBL2 genotypes and LP downregulating
variants in the blood donor cohort
The frequencies of the structural MBL2 variant alleles and
MBL2 genotypes are listed in Table 1. A total of 318 were
wild-type A/A (63.9 %), 168 were A/O (33.7 %) and 12 were
O/O (2.4 %). The A/O genotypes were genotyped for the
downregulating X variant in the MBL2 promoter. Forty-one
of the A/O genotypes were found to harbour the X variant, i.e.
25 XA/B, 1 XA/C and 15 XA/D. Thus, 53 of the blood donors
(10.6 %) wereMBL deficient (XA/O andO/O genotypes). The
calculated allele frequencies of the downregulating variants
FCN2+ 6424, FCN3+ 1637delC and MASP2 p.D120G in
the blood donors are shown in Table 2. Six individuals were
homozygous for the FCN2+6424 variant (T/T). In contrast,
neither for the FCN3+ 1637delC variant nor the MASP2
p.D120G variant was detected in the healthy cohort.
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Distributon of the FCN2+6424 variant amongMBL2,
FCN3 andMASP2 genotypes
A total of 93 subjects in the blood donor cohort carried the
FCN2+6424 variant and the calculated gene frequency was
0.099 (Table 2). Figure 1a demonstrates how the variant was
distributed among the five known MBL2 genotypes. Allele
frequency did not significantly differ between the MBL2 ge-
notypes; however, the frequency was substantially low in A/D
genotype carriers (0.043) and the variant was absent in O/O
genotypes (Fig. 1a). The comparison of FCN2+ 6424 fre-
quency among O/O and A/D genotypes (n=58) versus the
A/A, A/B and A/C genotypes (n=440) resulted in significant
difference (0.034 versus 0.108, P=0.013, chi-square test).
Interestingly, the six FCN2 + 6424 homozygotes (T/T)
(Table 2) were only found among wild-typeMBL2 genotypes
(A/A), whereas no homozygotes were found among individ-
uals carrying theMBL2 structural alleles (A/O and O/O geno-
types). The FCN2+6424 frequency did not differ between the
heterozygous carriers of FCN3+1637delC versus wild-type
(Fig. 1b) and the heterozygous carriers of MASP2p.D120G
versus wild-type (Fig. 1c).
The FCN2+6424 variant in MBL deficiency
Previous studies indicate that ficolin-2 may be compensating
for the lack of MBL (Ishii et al. 2011). Thus, we hypothesized
that the FCN2+6424 variant may be rare in MBL deficiency
due to its downregulating effect on ficolin-2 levels (Kilpatrick
et al. 2013; Munthe-Fog et al. 2007). The study cohort was
divided into those carrying MBL-sufficient genotypes (A/A
and AY/O) (n=445) and those carrying MBL-deficient geno-
types (AX/O and O/O) (n=53) according to previous sugges-
tions (Eisen et al. 2008). Subsequently, the FCN2+6424G>T
allele frequency was determined in each group. The observed
frequency of the variant tended to be lower in the MBL-
deficient group than in the MBL-sufficient group (0.047 ver-
sus 0.0106, P=0.054, chi-square test) (Fig. 1d).
Distributon of the FCN3+1637delC variant
amongMBL2, FCN2 andMASP2 genotypes
There were 15 heterozygote carriers of the FCN3+1637delC in
the blood donor cohort and calculated gene frequencywas 0.015
(Table 2). The variant was equally distributed among the five
knownMBL2 genotypes (Fig. 2a). The high frequency that was
observed in theA/C genotype subgroupmay be explained by the
small size of the group (n=8). The variant was absent in O/O
genotype carriers. No significant deviations were found in
FCN3 + 1637delC frequency between FCN2 genotypes
(Fig. 2b). Notably, four subjects were identified who were het-
erozygous for both downregulating variants in the ficolin genes,
i.e. FCN3+1637delC (-/C) and FCN2+6424 (G/T) (central bar
in Fig. 2b). Thus, healthy individuals have intermediate serum
levels of both ficolin-3 and ficolin-2. Interestingly, these four
individuals were all high producers of MBL (two AY/AY geno-
types, one AY/B genotype and one AY/C genotype). In contrast,
neither FCN3+ 1637delC nor FCN2+ 6424 were detected
among O/O subjects which have undetectable MBL in serum.
The FCN3+1637delC allele was equally distributed between
wild-type and heterozygoteMASP2p.D120G carriers (Fig. 2c).
The FCN3+1637delC variant in MBL deficiency
We hypothesized that the FCN3+1637delC variant would be
rare in MBL deficiency due to its downregulating effect on
ficolin-3 levels (Munthe-Fog et al. 2009). One individual was
heterozygous in the MBL-deficient group whereas 14 were
found in the MBL-sufficient group (Fig. 2d). The only
FCN3+1637delC carrier in the MBL-deficient group was an
AX/D genotype carrier.
Frequency ofMASP2p.D120G among theMBL2, FCN2
and FCN3 genotypes
We included the MASP2p.D120G variant in our analysis. It
causes downregulation of MASP-2 in a gene-dose-dependent
Table 1 Distribution ofMBL2
genotypes and structural variant
frequencies in the cohort
No. (%) of blood donors (n = 498) Allele frequencies
A/A A/B A/C A/D B/B B/D D/C pB pC pD
318 (63.9) 114 (22.9) 8 (1.6) 46 (9.2) 7 (1.4) 4 (0.8) 1 (0.2) 0.13 0.01 0.05
Table 2 Frequency of the
downregulating LP variants in the
cohort
Variant No. (%) wild types No. (%)
heterozygotes
No. (%)
homozygotes
Allele
frequency
FCN2+ 6424 G>T 405 (81) G/G 87 (17.5) G/T 6 (1.2) T/T 0.099
FCN3+ 1637delC 483 (97) C/C 15 (1.5) -/C 0 (0) -/- 0.015
MASP2p.D120G A > G 459 (92) A/A 39 (3.9) A/G 0 (0) G/G 0.039
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manner that is the same effect of the FCN2 + 6424 and
FCN3+ 1637delC variants. The MASP-2 protein is an en-
zyme activator of the LP and not one of the six recognition
proteins of the LP. Thus, the compensation hypothesis would
not be applied to this variant and one would not expect the
frequency to differ. There were 39 MASP2p.D120G het-
erozygote carriers in the blood donor cohort and calcu-
lated gene frequency was 0.039 (Table 2). The observed
gene frequency of MASP2p.D120G did not differ be-
tween MBL2 genotypes, FCN2 genotypes or FCN3 ge-
notypes (Fig. 3a–c). The elevated frequency in the A/C
(n= 8) and T/T (n= 6) subgroups (0.143 and 0.083, re-
spectively) may be due to the small number of individ-
uals in these groups. The variant was absent in O/O
genotype carriers (Fig. 2a). The frequency was low in
MBL-deficient subjects but not statistically different
from MBL-sufficient subjects (Fig. 3d).
Discussion
The observed occurrence ofMBL2 A/A and A/O genotypes in
the blood donors is similar as has been observed among ran-
domly selected individuals from a population of same ethnic
origin (Dahl et al. 2004; Garred et al. 2006; Mead et al. 1997;
Roy et al. 2002). However, only 2.4 % of the blood donors
were of theO/O genotype whereas we have observed this ratio
to be 5.6 % among randomly selected individuals from the
Icelandic nation (n = 250, unpublished data). Similar
findings have been observed in other studies. The ratio
of O/O genotypes was 5–7 % when selected randomly
(Dahl et al. 2004; Davies et al. 1995; Roy et al. 2002)
but 2.5–2.8 % when selected for health (Kronborg et al.
2002; Lee et al. 2005). Furthermore, none of the O/O
subjects in our healthy cohort were carriers of the downregu-
lating variants (FCN2 + 6424, FCN3 + 1637delC or
Fig. 1 Frequency of the FCN2 +
6424 G> T variant among
different genotypes in the blood
donor cohort (n= 498). a
Frequency among MBL2
genotypes; A/A (n= 318), A/B
(n = 114), A/C (n= 8), A/D
(n = 46), O/O (n = 12). b
Frequency between wild type
(WT) (n = 483) and carriers of the
FCN3+ 1637delC variant
(n = 15). c Frequency between
wild type (n= 459) and carriers of
the MASP2D120G variant
(n = 39). d Frequency between
MBL-sufficient genotypes
(n = 445) and MBL-deficient
genotypes (n = 53). Allele
frequency was compared with the
Kruskal-Wallis test followed by
Dunn’s multiple comparison pos
hoc test (a) and the chi-square test
(b–d)
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p.D120G). Thus, by selecting for health, one may expect to
observe twofold fewer O/O genotypes than from a ran-
dom selection and they may not be carriers of the
downregulating LP variants. Therefore, being an O/O
genotype carrier may be relevant when it comes to
health and may be linked to morbidity, particularly
when there is an additional LP component deficiency.
The observed gene frequency of the FCN2+6424 variant
(0.099) in the Icelandic Caucasian blood donors (n=498) is
slightly lower than has been observed for Dutch (n=188)
(0.136) and Danish Caucasian (n=214) (0.118) blood donors
and Dutch Caucasian (n = 1268) (0.137) kidney donors
(Damman et al. 2012; Herpers et al. 2006; Munthe-Fog et al.
2007). Our results (from this study and unpublished) demon-
strate that the downregulating FCN2+6424 variant tends to
be less frequent in MBL-deficient than in MBL-sufficient
subjects. Supporting this observation are the findings of Ishii
et al. who reported elevated levels of ficolin-2 among O/O
genotypes (Ishii et al. 2011). Thus, ficolin-2 may be compen-
sating for the lack of MBL. This conclusion is supported by
the facts that ficolin-2 and MBL resemble in molecular struc-
ture, they are both produced in the liver, they both initiate the
LP of complement via associated MASPs and they have been
shown to bind a wide variety of pathogens some of which are
in common (Degn and Thiel 2013; Kilpatrick and Chalmers
2012). It is conceivable that ficolin-2 is upregulated due to the
lack of MBL, but we speculate, based on our results, that
elevated ficolin-2 levels among O/O genotypes is due
to the rarity of the downregulating FCN2+ 6424 variant
among MBL-deficient individuals. Thus, there may be a
certain beneficial balance between MBL and ficolin-2
serum concentration for the host that has been main-
tained throughout evolution, and this may be controlled
by the genetic variants.
Fig. 2 Frequency of the FCN3 +
1637delC variant among different
genotypes in the blood donor
cohort (n = 498). a Frequency
among MBL2 genotypes; A/A
(n = 318), A/B (n = 114), A/C
(n = 8), A/D (n = 46), O/O
(n = 12). b Frequency amongwild
type (WT) (n= 483),
heterozygous carriers of FCN2+
6424 (G/T) (n= 87) and
homozygous carriers of FCN2+
6424 (T/T) (n= 6). c Frequency
between wild type (n= 459) and
carriers of the MASP2D120G
variant (A/G) (n= 39). d
Frequency between MBL-
sufficient genotypes (n= 445) and
MBL-deficient genotypes
(n = 53). Allele frequency was
compared with the Kruskal-
Wallis test followed by Dunn’s
multiple comparison pos hoc test
(a) and the chi-square test (b–d)
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The low gene frequency ofFCN3+1637delC and the small
sample size of the blood donor cohort preclude significant
conclusions regarding the FCN3 + 1637delC gene fre-
quency in MBL deficiency or low producers of
ficolin-2 (FCN2+ 6424 homozygotes). Therefore, further
investigations in a cohort with a larger number of MBL-
deficient genotypes and FCN2+ 6424 homozygotes are
warranted. The only FCN3+ 1637delC carrier found in
the MBL-deficient group of our study cohort was of the
XA/D genotype. Notably, the D variant is believed to
have less dramatic effect on MBL levels than the B or
C variants. The D variant chain is partly incorporated
into stable higher oligomerized MBL explaining why
MBL levels are generally higher among A/D genotypes
than A/B and A/C genotypes (Garred et al. 2003).
Furthermore, some investigators state that D allele car-
riers are intermediate MBL producers and should not be
grouped as deficient (Degn et al. 2011). We have
screened additional MBL-deficient adults (n= 140) for
the FCN3+ 1637delC variant and found only one het-
erozygote carrier, and this individual was also of the
XA/D genotype (unpublished data), further supporting
our findings demonstrated here. Interestingly, homozy-
gosity for FCN3+ 1637delC accompanied with the AX/
D genotype was recently confirmed in an 11-month-old
infant with congenital heart disease, pneumonia (without
recurrence) and no severe infections after cardiac sur-
gery (Michalski et al. 2015b). Thus, being a carrier of
the FCN3+ 1637delC deletion and of the AX/D geno-
type does not seem to be life-threatening and not asso-
ciated with severe recurrent infections.
Remarkably, the FCN3+1637delC variant was not found
among subjects carrying genotypes O/O, AX/B, and AX/C.
Thus, we speculate that having intermediate ficolin-3 levels
Fig. 3 Frequency of the
MASP2D120G variant among
different genotypes in the blood
donor cohort (n= 498). a
Frequency among MBL2
genotypes; A/A (n= 318), A/B
(n = 114), A/C (n= 8), A/D
(n = 46), O/O (n = 12). b
Frequency among wild type
(n = 483), heterozygous carriers
of FCN2+ 6424 (G/T) (n= 87)
and homozygous carriers of
FCN2+ 6424 (T/T) (n= 6). c
Frequency between wild type
(n = 483) and carriers of the
FCN3+ 1637delC variant (-/C)
(n = 15). d Frequency between
MBL-sufficient genotypes
(n = 445) and MBL-deficient
genotypes (n = 53). Allele
frequency was compared with the
Kruskal-Wallis test followed by
Dunn’s multiple comparison pos
hoc test (a) and the chi-square test
(b–d)
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or ficolin-3 deficiency accompanied with severe MBL defi-
ciency (excluding theD variant, i.e. genotypesO/O, AX/B and
AX/C) may have a substantial impact as co-morbid factor. In
fact, the only individual that has been reported to be both
FCN3+ 1637delC homozygous and of the O/O genotype
was a premature baby (born at 35 weeks of gestation) with
perinatal Streptococcus agalactiae infections, microcephaly,
growth and mental retardation, and was diagnosed with
attention deficit hyperactivity disorder (ADHD) at
3 years of age (Michalski et al. 2011). It has been
suggested that ficolin-3 may be relevant in controlling
commensal intestinal flora (Michalski et al. 2015a), and
our previous studies show that O/O individuals are
highly susceptible to gastrointestinal (GI) symptoms
(Bjarnadottir et al. 2014). Thus, ficolin-3 and MBL
may be relevant in the establishment of the gut micro-
biota at infancy. Recently, much attention has been on
the association of the gut microbiota and microbiome
with various disorders (Dave et al. 2012; Wang and
Kasper 2014). Given the potential role of the LP in
these complex interactions of the gut microbiota with
its host and our findings reported here warrant further
investigations on the impact of combined ficolin-3 and
MBL deficiencies on microbiota and human health.
The observed frequency of the p.D120G allele in the
Icelandic blood donor group is compatible with other
studies including healthy Caucasians (Thiel et al.
2007). What we found noteworthy was that among the
MBL deficiency genotypes, the variant was only associated
with AX/B subjects and not with AX/D and O/O sub-
jects. Ishii et al. reported significantly elevated levels of
MASP-2 among O/O genotypes (Ishii et al. 2011). It is
conceivable that MASP-2 was elevated in O/O geno-
types because the downregulating variant p.D120G is
absent. Furthermore, none of the 14 published p.D120G ho-
mozygotes were MBL deficient (personal communication)
(Cedzynski et al. 2009; Cedzynski et al. 2004; Garcia-
Laorden et al. 2008; Olesen et al. 2006; Sokolowska et al.
2015; Stengaard-Pedersen et al. 2003). Thus, we speculate
that it may not be beneficial for the host to be a carrier of
p.D120G and MBL deficiency (excluding the AX/B geno-
type). In contrast, the p.D120G was found equally distributed
among sufficient (G/G), intermediate (G/T) and low producers
of ficolin-2 (T/T).
Our results demonstrate how various LP deficiency vari-
ants are distributed among various LP genotypes in healthy
individuals. In continuation, this data may become use-
ful as a reference in disease association studies.
Employing LP variant distribution pattern analysis in
case-control studies may not replace determining the
patterns of serum levels, but it may be an alternative and
perhaps an innovative approach to investigate the impact of
the LP on human health.
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